Oxford University Innovation, the University of Oxford’s technology transfer company, achieved increased revenues of £5.6 million in the last financial year, up 18 per cent from the previous year.
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
Emergent Biosolutions and the University of Oxford form joint venture to develop an advanced tuberculosis vaccine with funding from Wellcome Trust and Aeras Global TB Vaccine Foundation.
Oxford Advanced Surfaces (“OAS”), a spin-out company of the University of Oxford, has listed on the Alternative Investment Market (AIM), and has achieved a market capitalisation of £84.5 million
Oxford spin-outs have been busy raising finance. A total of nearly £50 million has been secured so far this year by some of the 50 companies spun-out by Oxford University Innovation from the University of Oxford, including those mentioned below.
Oxford University has signed a private equity deal, initially worth £12m, to help the funding of its new Institute of Biomedical Engineering (IBME) www.ibme.ox.ac.uk. The deal, struck with London’s City-based Technikos, also includes the provision of commercial and financial advice and assistance in return for shares in future spin-outs from IBME.
Oxitec Limited announces the completion of its second funding round of £1.3m, led by Oxford Capital Partners. The existing investors, East Hill Advisors, LLC from Boston and the University of Oxford (through the Isis College Fund), have made further investments in the company as part of this round. Oxford Capital Partners invested £550,000.
BioAnalab Limited, the Oxford-based specialist contract analytical laboratory, today announced the successful completion of a further round of private equity funding totalling £440,000. The round was led by Octopus Asset Management, who invested £250,000 through the BioScience Venture Capital Trust.